Plant Name: Rosa transmorrisonensis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 8.686E-14 | 1.719E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.138E-11 | 1.906E-08 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 2.921E-11 | 4.543E-08 | CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.991E-11 | 6.793E-08 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR2, PPARA, PPARD |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.744E-10 | 1.809E-07 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.889E-10 | 2.735E-07 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.741E-09 | 1.865E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.424E-09 | 2.919E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.115E-08 | 6.744E-06 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NPC1, PPARD |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.298E-08 | 7.638E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 2.113E-08 | 1.103E-05 | CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.177E-08 | 1.103E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 5.225E-08 | 2.370E-05 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.803E-08 | 3.332E-05 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.112E-07 | 4.483E-05 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 1.898E-07 | 7.005E-05 | CYP2A13, CYP2A6, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.483E-07 | 2.107E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 3.190E-06 | 9.514E-04 | CYP2A13, CYP2A6 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.742E-32 | 1.468E-27 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 3.994E-06 | 1.129E-03 | CA2, CA9, CYP1A2, FABP3, HPGD, NFKB1, NPC1, PPARD, TLR2 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 9.558E-06 | 2.538E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.558E-06 | 2.538E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:1901700; response to oxygen-containing compound | 1.013E-05 | 2.625E-03 | CA3, CA9, CYP1A2, FABP3, HPGD, MAPK1, NFKB1, PPARA, PPARD, TLR2, TSHR |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.014E-05 | 4.874E-03 | CA2, CA4, CA9, HPGD, TSHR |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 3.697E-05 | 8.475E-03 | CA2, CA9, CYP1A2, HPGD, MAPK1, NFKB1, NPC1, TLR2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.027E-24 | 3.296E-20 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.983E-23 | 3.801E-19 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.026E-31 | 8.196E-29 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.025E-09 | 9.182E-08 | CYP2C9; CYP2A6; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.862E-09 | 9.731E-08 | CYP2C9; CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP3A4 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 2.025E-09 | 9.182E-08 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.821E-09 | 1.583E-07 | CYP2C9; CYP2A6; CYP2A13; CYP1A2; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.809E-07 | 4.100E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.931E-06 | 9.581E-05 | CYP2C9; CYP2A6; CYP1A2; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.268E-05 | 6.449E-04 | CYP2C9; CYP2D6; MAPK1; CYP2C19 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.346E-04 | 1.831E-03 | MAPK1; NFKB1; PPARD |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.695E-04 | 3.182E-03 | MAPK1; NFKB1; ESR2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.911E-04 | 4.091E-03 | MAPK1; PPARA; NFKB1; TSHR |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 2.808E-04 | 3.182E-03 | MAPK1; NFKB1; TLR2 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 8.372E-04 | 7.116E-03 | MAPK1; NFKB1; TLR2 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 7.921E-04 | 7.116E-03 | MAPK1; NFKB1; TLR2 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.142E-03 | 9.134E-03 | MAPK1; NFKB1; TLR2 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.611E-03 | 1.217E-02 | MAPK1; PPARA; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.102E-03 | 1.429E-02 | MAPK1; NFKB1; TLR2 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.717E-03 | 1.229E-02 | RAB9A; NFKB1; TLR2 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 3.509E-03 | 2.169E-02 | XPO1; MAPK1; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 3.680E-03 | 2.176E-02 | MAPK1; NFKB1; TLR2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 4.318E-03 | 2.329E-02 | FABP4; TSHR |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 4.168E-03 | 2.329E-02 | NFKB1; TLR2 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.934E-03 | 1.900E-02 | CYP2A6; CYP3A4 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 7.355E-04 | 7.116E-03 | CA2; CA4 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 5.949E-03 | 2.610E-02 | MAPK1; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 5.775E-03 | 2.610E-02 | NFKB1; TLR2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.267E-03 | 2.558E-02 | CYP2C9; CYP2C19 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 4.470E-03 | 2.329E-02 | MAPK1; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 7.233E-03 | 2.811E-02 | MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 7.233E-03 | 2.811E-02 | MAPK1; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.348E-02 | 4.472E-02 | MAPK1; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.625E-03 | 2.329E-02 | CYP1A2; CYP3A4 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 6.669E-03 | 2.811E-02 | PPARA; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.059E-02 | 3.791E-02 | MAPK1; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.298E-02 | 4.472E-02 | MAPK1; ESR2 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 5.775E-03 | 2.610E-02 | MAPK1; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 6.854E-03 | 2.811E-02 | CA2; CYP3A4 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.323E-02 | 4.472E-02 | NFKB1; TLR2 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.612E-02 | 4.766E-02 | ACHE; MAPK1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.399E-02 | 4.507E-02 | MAPK1; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.425E-02 | 4.507E-02 | MAPK1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.585E-02 | 4.766E-02 | MAPK1; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 9.918E-03 | 3.645E-02 | MAPK1; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.558E-02 | 4.766E-02 | PPARA; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 7.621E-03 | 2.879E-02 | MAPK1; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.965E-05 | 5.041E-04 | CYP2A6; CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | XPO1; CA9; MAPK1; TLR2 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | Cancer | C00-C96 | XPO1; CA1; CA9; MAPK1; NFKB1; ACHE; TLR2 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE |